Costs of SGLT2 inhibitors and GLP-1 receptor agonists need to be lowered substantially to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.
Iran: The sodium-glucose co-transporter-2 (SGLT2) inhibitors improve some metabolic and anthropometric markers in individuals without diabetes who are overweight/obese, researchers state in a.
Adding the IV drug to loop diuretics in the ADVOR trial improved decongestion success in volume-overloaded patients with acute decompensated heart failure, researchers reported.